{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:20:07Z","timestamp":1787595607029,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"DOI":"10.7759\/cureus.115098","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:21:07Z","timestamp":1787592067000},"source":"Crossref","is-referenced-by-count":0,"title":["A Phase-Gated Protocol for Managing Mid-study Principal Investigator Transitions in Multi-site Investigational Device Exemption Trials"],"prefix":"10.7759","author":[{"given":"Sajan Sanjay","family":"Pandya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Investigational Device Exemptions, 21 CFR Part 812. (2026). Accessed. June 10, 2026: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H\/part-812."},{"key":"ref2","unstructured":"Financial disclosure by clinical investigators, 21 CFR Part 54. (2026). Accessed. June 10, 2026: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-A\/part-54."},{"key":"ref3","unstructured":"Premarket approval of medical devices, 21 CFR Part 814. (2026). Accessed. June 10. (2026). https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H\/part-814."},{"key":"ref4","unstructured":"FDA impact on U.S. medical technology innovation. a survey of over 200 medical technology companies. (2010). Accessed: June 10, 2026: https:\/\/www.medtecheurope.org\/wp-content\/uploads\/2015\/09\/01112010_FDA-impact-on-US-medical-technology-innovation_Back...."},{"key":"ref5","unstructured":"Celegence. Regulatory readiness and resources survey report 2024. (2026). Accessed. June 10, 2026: https:\/\/www.celegence.com\/downloads\/regulatory-readiness-and-resources-survey-report-2024\/."},{"key":"ref6","article-title":"ICH Harmonised Guideline: Guideline for Good Clinical Practice E6(R3)","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2025","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline: Guideline for Good Clinical Practice E6(R3). ICH, Geneva, Switzerland; 2025."},{"key":"ref7","article-title":"Medical Devices; Quality System Regulation Amendments. Final Rule","author":"Food and Drug Administration","year":"2026","unstructured":"Food and Drug Administration. Medical Devices; Quality System Regulation Amendments. Final Rule. Food and Drug Administration, North Bethesda, MD; 2026."},{"key":"ref8","article-title":"ISO 13485:2016: Medical Devices \u2014 Quality Management Systems \u2014 Requirements for Regulatory Purposes","author":"International Organization for Standardization","year":"2016","unstructured":"International Organization for Standardization. ISO 13485:2016: Medical Devices \u2014 Quality Management Systems \u2014 Requirements for Regulatory Purposes. International Organization for Standardization, Geneva, Switzerland; 2016."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-9929659\/v1","article-title":"Integrated prospective regulatory governance: a quality-by-design operating model for high-risk Class III medical device clinical investigations","author":"Pandya SS","year":"2026","unstructured":"Pandya SS. Integrated prospective regulatory governance: a quality-by-design operating model for high-risk Class III medical device clinical investigations. Res Sq. 2026, 10.21203\/rs.3.rs-9929659\/v1","journal-title":"Res Sq"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1740774516643491","article-title":"Enhancing clinical evidence by proactively building quality into clinical trials","volume":"13","author":"Meeker-O'Connell A","year":"2016","unstructured":"Meeker-O'Connell A, Glessner C, Behm M, et al.. Enhancing clinical evidence by proactively building quality into clinical trials. Clin Trials. 2016, 13:439-44. 10.1177\/1740774516643491","journal-title":"Clin Trials"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2021.837","article-title":"Feasibility and acceptability of a structured quality by design approach to enhancing the rigor of clinical studies at an academic health center","volume":"5","author":"Moradi H","year":"2021","unstructured":"Moradi H, Schneider M, Streja E, Cooper D. Feasibility and acceptability of a structured quality by design approach to enhancing the rigor of clinical studies at an academic health center. J Clin Transl Sci. 2021, 5:e175. 10.1017\/cts.2021.837","journal-title":"J Clin Transl Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1740774517724165","article-title":"Risk-adapted monitoring is not inferior to extensive on-site monitoring: results of the ADAMON cluster-randomised study","volume":"14","author":"Brosteanu O","year":"2017","unstructured":"Brosteanu O, Schwarz G, Houben P, et al.. Risk-adapted monitoring is not inferior to extensive on-site monitoring: results of the ADAMON cluster-randomised study. Clin Trials. 2017, 14:584-96. 10.1177\/1740774517724165","journal-title":"Clin Trials"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00417-w","article-title":"Descriptive analysis of Good Clinical Practice inspection findings from U.S. Food and Drug Administration and European Medicines Agency","volume":"56","author":"Sellers JW","year":"2022","unstructured":"Sellers JW, Mihaescu CM, Ayalew K, et al.. Descriptive analysis of Good Clinical Practice inspection findings from U.S. Food and Drug Administration and European Medicines Agency. Ther Innov Regul Sci. 2022, 56:753-64. 10.1007\/s43441-022-00417-w","journal-title":"Ther Innov Regul Sci"},{"key":"ref14","unstructured":"ClinicalTrials.gov. Encore Medical Inc.. Encore PFO Closure Device - The PerFOrm Trial (NCT05537753). (2024). https:\/\/clinicaltrials.gov\/study\/NCT05537753."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/506916-a-phase-gated-protocol-for-managing-mid-study-principal-investigator-transitions-in-multi-site-investigational-device-exemption-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:21:09Z","timestamp":1787592069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/506916-a-phase-gated-protocol-for-managing-mid-study-principal-investigator-transitions-in-multi-site-investigational-device-exemption-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.115098","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}